2,115 press releases in English indexed under biotech & pharma.
Company to host conference call and webcast on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time SAN DIEGO, October 21, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the U
SAN FRANCISCO, October 21, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4 to provide a corporate update and discuss its financial results for the third quarter ended September 30, 2026. The confere
VERAXA is implementing FDA-aligned New Approach Methodologies (“NAMs”) across its preclinical research programs, aiming to improve the relevance of experimental findings to human biology while reducing animal testing. The strategy supports development of the company’s BiTAC(R) T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for the treatment of cancer. New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. An ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer required about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. LOS ANGELES, CA - October 21, 2026 - VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is expanding its use of human-relevant testing methods across its oncology research programs, seeking to generate more clinically informative preclinical data while reducing the number of animals required for drug development. In an October 7, 2026, company announcement, the Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., outlined its implementation of New Approach Methodologies (“NAMs”), a collection of non-animal research techniques that includes cell-based assays, computational modeling and… Read More Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
Lawsuit alleges Unicycive Therapeutics, Inc. made misleading statements to investors from December 29, 2025 to June 29, 2026; lead plaintiff motions are due November 2, 2026 LOS ANGELES, Oct. 21, 2026 -- The Law Offices of Frank R. Cruz today announced a class action lawsuit...
MIAMI, Oct. 21, 2026 -- Global law firm Greenberg Traurig, P.A. advised OPKO Health, Inc., a multinational biopharmaceutical company, on its agreement to sell select assets of its wholly owned subsidiary, BioReference Health, LLC, to Labcorp. The purchase price for the...
NEW YORK, Oct. 21, 2026 -- A new clinical trial funded by Breakthrough T1D recently launched and is testing islet cell transplantation paired with Eledon Pharmaceuticals' investigational immunosuppression therapy tegoprubart in people living with type 1 diabetes (T1D) and...
WSW, NY, 21st October 2026, FinanceWire … Read More The post Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN) appeared first on FinanceWire - Financial Press Release Distribution, Finance PR.
-- Post-Hoc Analysis of the Phase 2/3 IMPALA Clinical Trial Presented in a Poster Presentation at the CHEST 2026 Annual Meeting -- YARDLEY, Pa., October 21, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a post
Discovery may help develop treatments for Andes virus and other hantaviruses BRONX, N.Y., Oct. 21, 2026 -- Earlier this year, an outbreak of Andes hantavirus on a cruise ship, which killed three passengers and sickened 13, highlighted the lack of approved vaccines or...
The global oral drugs market is experiencing steady growth, driven by the increasing prevalence of chronic diseases and the growing demand for convenient, patient-friendly treatment options. The expansion of oral therapies across therapeutic areas such as oncology, diabetes, cardiovascular diseases, and neurological disorders is further supporting market development. In addition, the availability of generic and branded oral drugs, expanding healthcare access, and rising pharmaceutical R&D investments are contributing to market expansion. The global oral drugs market is experiencing steady growth, driven by the increasing prevalence of chronic diseases and the growing demand for convenient, patient-friendly treatment options. The expansion of oral therapies across therapeutic areas such as oncology, diabetes, cardiovascular diseases, and neurological disorders is further supporting market development. In addition, the availability of generic and branded oral drugs, expanding healthcare access, and rising pharmaceutical R&D investments are contributing to market expansion.
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm's continued expansion of its biotech offering. Young joined William Blair in May 2026 as part of a broader investment in the firm's equitie
Median Technologies is a leading provider of central imaging services and AI-powered image analysis for oncology clinical trials The Company will host an interactive session on the implementation of RANO 2.0 in central imaging review for neuro-oncology trials at booth #1098 The Company will also present an ePoster on the